Telix Pharmaceuticals Limited
TLX
$10.68
-$0.06-0.54%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -134.29% | -134.29% | -115.08% | -109.70% | -3.61% |
| Total Depreciation and Amortization | 299.72% | 299.72% | 200.98% | 472.92% | 84.61% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -89.47% | -89.47% | -50.16% | 157.72% | 127.70% |
| Change in Net Operating Assets | -5.12% | -5.12% | -- | -- | -64.18% |
| Cash from Operations | -942.76% | -942.76% | -54.91% | 146.61% | 28.30% |
| Capital Expenditure | -214.45% | -214.45% | -125.41% | -113.01% | -52.40% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 108.46% | 108.46% | -637.46% | -- | -617.26% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 79.60% | 79.60% | -51.41% | -162.04% | -357.20% |
| Cash from Investing | 51.89% | 51.89% | -428.60% | -2,108.35% | -292.13% |
| Total Debt Issued | -99.88% | -99.88% | -- | -- | 15,326.65% |
| Total Debt Repaid | -92.71% | -92.71% | -128.65% | -- | -138.85% |
| Issuance of Common Stock | 367.77% | 367.77% | 8.61% | 107.36% | -86.64% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.19% | -100.19% | -160.91% | -51.70% | 10,182.43% |
| Foreign Exchange rate Adjustments | -4.47% | -4.47% | 321.34% | 94.33% | -178.68% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -118.09% | -118.09% | -2,260.96% | -33,364.07% | 8,768.84% |